MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Alvotech

< Previous 1 2 3 4 5 Next >
News headline image
Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab)
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept)
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
Alvotech Announces Webcast on November 13, 2025 to Report Financial Results for the First Nine Months of 2025 and Provide a Business Update
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
Alvotech Announces Changes in Global Business Development and Commercial Operations Team
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech’s Proposed Biosimilar to Prolia® and Xgeva®
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech’s Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
Alvotech Announces Marketing Approval in Japan of Three New Biosimilars
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee in Switzerland
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
Alvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia® (certolizumab pegol)
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
Alvotech’s Lenders Lower Interest on Senior Secured Term Loan Facility
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
Main Results of 2025 Annual and Extraordinary General Meeting
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
European Medicines Agency Recommends Market Approval of AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept)
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
Alvotech Meets Investors and Presents at the Goldman Sachs Global Healthcare Conference in Miami
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)
From Alvotech
Via GlobeNewswire
Tickers ALVO RDY
News headline image
Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
Alvotech Meets Investors and Presents at the Jefferies Global Healthcare Conference 2025 in New York, NY
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Three Additional Biosimilars in Europe
From Alvotech
Via GlobeNewswire
Tickers ALVO
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story